Differential Survival Benefits of 5-Fluorouracil–Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis
This study aimed to investigate the clinical benefits of adjuvant chemotherapy according to the tumor budding status in microsatellite-stable stage III colorectal cancer.
DESIGN:
This was a retrospective study of 2 cohorts.
SETTINGS:
The study was conducted at the National Defense Medical College in Japan.
PATIENTS:
We reviewed 2 data sets of patients with microsatellite-stable stage III colorectal cancer with curatively intended surgery (R0) from 1999 to 2005 (first cohort; n = 203) and 2006 to 2012 (second cohort; n = 346). In both cohorts, 128 and 203 patients received 5-fluorouracil–based adjuvant chemotherapy and 75 and 143 patients did not.
MAIN OUTCOME MEASURES:
We assessed the benefits of adjuvant chemotherapy according to the grades of tumor budding based on the cancer-specific survival.
RESULTS:
In low-budding tumors, the chemotherapy group exhibited better cancer-specific survival than the surgery-alone group (first cohort, 93.1% vs 65.5%, p = 0.001; second cohort, 94.0% vs 76.0%, p
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Gastroenterology | Japan Health | Study